Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to experimental motion

Trial Profile

A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to experimental motion

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Seliforant (Primary) ; Meclozine
  • Indications Tinnitus; Vertigo
  • Focus Pharmacodynamics
  • Sponsors Sensorion
  • Most Recent Events

    • 14 Dec 2018 Top-line results presented in a Sensorion media release.
    • 27 Nov 2018 According to a Sensorion media release, subject enrolment and dosing has been completed in this trial.
    • 27 Nov 2018 Status changed from recruiting to active, no longer recruiting, as reported in the Sensorion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top